Genprex is raising the standard in cancer treatment by developing what it calls an “immunogene therapy,” which harnesses the power of immunotherapy’s immunomodulation through the delivery of a gene therapy.
Independent researchers reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex™ immunogene therapy, prevented tumor growth in triple-negative breast cancer (TNBC).
Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company's presentation on September 9, 2019 in New York City.
These anticipated milestones and future guidance are incorporated into the latest update of the company’s corporate presentation, which can be found at Genprex.com.
The passion for gene therapy and the new era of cell and gene-based medicine has made its way to the mainstream for treatment of serious diseases.
Genprex's Chairman and Chief Executive Officer, Rodney Varner, is scheduled to present at the 4th Annual Disruptive Growth Conference in New York City on September 4, 2019.
Company’s recent performance sets path for future milestones, commercialization
Genprex's newly manufactured plasmids will be used in clinical trials evaluating Oncoprex™ in combination with targeted therapies and immunotherapies.
Genprex has initiated the first phase of branding its lead drug candidate and has completed the creation and submission of non-proprietary drug name selections to the American Medical Association’s United States Adopted Names (USAN) Council.
Genprex is working on developing its initial drug candidate for NSCLC that would potentially benefit a large patient population who cannot currently benefit from approved therapies.